Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Camille Gérard"'
Autor:
Fanny S. Krebs, Camille Gérard, Alexandre Wicky, Veronica Aedo-Lopez, Edoardo Missiaglia, Bettina Bisig, Mounir Trimech, Olivier Michielin, Krisztian Homicsko, Vincent Zoete
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 21, p 8021 (2020)
We report a case of an uveal melanoma patient with GNAQ p.Gly48Leu who responded to MEK inhibition. At the time of the molecular analysis, the pathogenicity of the mutation was unknown. A tridimensional structural analysis showed that Gαq can adopt
Externí odkaz:
https://doaj.org/article/8b601cb30f094e7ea5e5472d01ca60e2
Autor:
Alexandre Wicky, Roberto Gatta, Sofiya Latifyan, Rita De Micheli, Camille Gerard, Sylvain Pradervand, Olivier Michielin, Michel A. Cuendet
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
The growing availability of clinical real-world data (RWD) represents a formidable opportunity to complement evidence from randomized clinical trials and observe how oncological treatments perform in real-life conditions. In particular, RWD can provi
Externí odkaz:
https://doaj.org/article/f85c02fb24b741168c0403f2819666f4
Autor:
Lisa Zimmer, Serigne Lo, Celeste Lebbe, Olivier Michielin, Ines Pires da Silva, Paolo Antonio Ascierto, Matteo Carlino, Alexander Menzies, Douglas B Johnson, Claudia Trojanello, Georgina Long, Tasnia Ahmed, Clara Allayous, Johanna Mangana, Florentia Dimitriou, Danny Zakria, Camille Gerard
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 7 (2022)
Background Patients with V600BRAF mutant metastatic melanoma have higher rates of progression-free survival (PFS) and overall survival (OS) with first-line anti-PD1 (PD1]+anti-CTLA-4 (IPI) versus PD1. Whether this is also true after BRAF/MEKi therapy
Externí odkaz:
https://doaj.org/article/21c29e95030742fcaad36b5414ae6fcf
Autor:
Robyn Gartrell, Douglas Marks, Thomas Hart, Yan Lu, Ed Stack, Camden Esancy, Basil Horst, Yvonne Saenger, Camille Gerard, Dan Tong Jia, Paul Armenta, Daisuke Izaki, Kristen Beck
Publikováno v:
Journal of Clinical and Translational Science, Vol 1, Pp 62-63 (2017)
OBJECTIVES/SPECIFIC AIMS: Precise biomarkers are urgently needed to characterize the tumor immune microenvironment in primary melanoma tumors both for prognostication and to predict the benefit of immuno-therapeutic intervention. The goal of this wor
Externí odkaz:
https://doaj.org/article/b40f21808f054dc9be5403bb4879ba0e